Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29672346 | 1.00 | HDAC6 (0.51) | HDAC6HDAC8HDAC4HDAC7HDAC11 | |
| SCHEMBL22944075 | 0.92 | HDAC6 (0.54) | HDAC6HDAC8HDAC4HDAC7HDAC11 | |
| SCHEMBL22944079 | 0.90 | HDAC6 (0.54) | HDAC6HDAC8HDAC4HDAC7HDAC11 | |
| SCHEMBL27229878 | 0.86 | HDAC6 (0.37) | HDAC6HDAC8HDAC4HDAC7HDAC11 | |
| SCHEMBL29672378 | 0.86 | HDAC6 (0.37) | HDAC6HDAC8HDAC4HDAC7HDAC11 | |
| SCHEMBL22944943 | 0.82 | HDAC6 (0.44) | HDAC6HDAC8HDAC4HDAC7HDAC11 | |
| SCHEMBL29795160 | 0.82 | HDAC6 (0.47) | HDAC6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL22944077 | 0.81 | HDAC6 (0.50) | HDAC6HDAC8HDAC4HDAC7HDAC11 | |
| SCHEMBL26055254 | 0.80 | HDAC6 (0.45) | HDAC6HDAC8HDAC4HDAC7HDAC11 | |
| SCHEMBL22943797 | 0.79 | HDAC6 (0.50) | HDAC6HDAC8HDAC4HDAC7HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114727974-A | HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021021979-A2 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC8 8/4885HDAC4 11/4885 |
| US-20240174616-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC8 9/4885HDAC4 11/4885 |
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC8 11/4885HDAC4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.